Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan PK in Breast Milk
NCT06391177Phase 1Completed
- Sponsor
- Phathom Pharmaceuticals
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vonoprazan in erosive esophagitis (EE), gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (2 arms), sponsored by Phathom Pharmaceuticals. Primary endpoints: Area Under Drug Concentration-time Curve From Time 0 to 24 Hours, Maximum Drug Concentration and 3 more. Started May 2024; status: completed.
02
Drugs
vonoprazan
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06391177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391177.